ArticleAmerican journal of translational research2023
Resveratrol enhances MUC2 synthesis via the ANRIL-miR-34a axis to mitigate IBD.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Resveratrol for inflammatory bowel disease in preclinical studies: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Article
- ceRNA Network Dynamics in Inflammatory Bowel Disease: The LncRNA-miRNA-mRNA Axis in Intestinal Homeostasis and Inflammation.Cell biochemistry and biophysics · 2026Review
- Long non-coding RNA ANRIL/p65 negative feedback loop protects intestinal barrier function in inflammatory bowel disease.Non-coding RNA research · 2025Article
- Long Non-Coding RNAs and Their Potential Role as Biomarkers in Inflammatory Bowel Disease.International journal of molecular sciences · 2024Review
- Long Non-Coding RNA ANRIL Regulates Inflammatory Factor Expression in Ulcerative Colitis Via the miR-191-5p/SATB1 Axis.Inflammation · 2024Article
- The emerging role of oxidative stress in inflammatory bowel disease.Frontiers in endocrinology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsResveratrol (RSV) is a natural polyphenol with strong biological activity that confers a measure of protection against the development of inflammatory bowel disease (IBD), and the long noncoding RNA (lncRNA) antisense non-coding RNA in the INK4 locus (ANRIL) is closely related to inflammation. The present study determined whether resveratrol attenuated IBD by regulating ANRIL and its specific molecular mechanism.
methodsIn vivo model of IBD was induced by dextran sulfate sodium (DSS). In total, 60 BALB/c mice were randomly divided into 3 groups (normal control - NC, DSS, RSV), and their weight changes, fecal traits, colon length and tissue hematoxylin-eosin (H&E) were observed. Moreover, human colonic epithelial cells (HCoEpiC) treated with lipopolysaccharide (LPS) were used as cell models of IBD. The tumor necrosis factor α (TNF-α), interleukin (IL)-1β, IL-6, IL-10, lncRNA ANRIL, and miR-34a levels were measured by RT-PCR. The expression of mucin 2 (MUC2) and an enzyme associated with MUC2 synthesis, polypeptide N-acetylgalactosaminyltransferase 7 (GALNT7), was measured by RT-PCR and western blot analysis.
resultsResveratrol treatment mitigated colitis by significantly decreasing the expression of pro-inflammatory cytokines (i.e. TNF-α, IL-1β, IL-6) and miR-34a, and increasing the levels of anti-inflammatory cytokine (i.e. IL-10), MUC2, GLNAT7, and lncRNA ANRIL in mice and HCoEpiC (all P<0.05). The elevated synthesis of MUC2 could be attributed to the ANRIL-miR-34a axis.
conclusionsResveratrol attenuates IBD by promoting MUC2 synthesis via the ANRIL-miR-34a axis.
Indexed as
Identifiers
36777862PMC9908457What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.